MI portfolio company actively seeking additional products for licensing and development
TORONTO and SAN DIEGO, Jan. 9, 2014 — A unique collaboration of life science leaders, including the Fight Against Cancer Innovation Trust, MaRS Innovation Ventures Trust and MaRS Phase II Investment Trust, have formed Triphase Accelerator Corporation, an oncology development accelerator.
Triphase Accelerator's announcement was covered in Yonge Street Media, Bloomburg Businessweek and Global University Venturing.
Formed in 2010, Triphase Accelerator Corporation is a cancer-focused biotechnology development company that aims to reduce the ...
TORONTO, Ontario, Canada – October 24, 2011 – DLVR Therapeutics Inc. (“DLVR”) - a privately-held biotechnology company currently focused on developing oncology therapeutics based on its proprietary high density lipoprotein-like nanoparticle - announced today that the company has completed its seed round investment bringing the total raised to $2 million in cash and in-kind support. MaRS Innovation joins the University Health Network (UHN) and the Ontario Institute for Cancer Research (OICR) as investors in the company. The additional funds will be ...